Key result
Cardiac resynchronization therapy failed to restore the significantly decreased levels of regulatory T cells in patients with chronic heart failure at 6 months follow-up.
Why the study?
Cardiac resynchronization therapy improves symptoms and cardiac remodeling in chronic heart failure, but its impact on the inflammatory immune response remains controversial.
Does cardiac resynchronization therapy restore T regulatory cell homeostasis in patients with chronic heart failure?
Cohort (n=50)
No
Does cardiac resynchronization therapy restore T regulatory cell homeostasis in patients with chronic heart failure?
Answers are grounded in this paper and cite their sources.
Cardiac resynchronization therapy does not restore the diminished levels of regulatory T cells or inhibit pro-inflammatory T cell pathways in patients with chronic heart failure.
Background: T cells have been implicated in the development and progression of inflammatory process in chronic heart failure (CHF). Cardiac resynchronization therapy (CRT) has beneficial effects on symptoms and cardiac remodeling in CHF. However, its impact on the inflammatory immune response remains controversial. We aimed to study the impact of CRT on T cells in heart failure patients (HFP). Methods: Thirty-nine HFP were evaluated before CRT (T0) and 6 months later (T6). Quantification of T cells, their subsets, and their functional characterization, after in vitro stimulation, were evaluated by flow cytometry. Results: T regulatory (Treg) cells were decreased in CHF patients (healthy group (HG): 1.08±0.50 versus HFP-T0: 0.69±0.40, P=0.022) and remaining diminished after CRT (HFP-T6: 0.61±0.29, P=0.003). Responders (R) to CRT presented a higher frequency of T cytotoxic (Tc) cells producing IL-2 at T0 compared with non-responders (NR) (R: 36.52±12.55 versus NR: 24.71±11.66, P=0.006). After CRT, HFP presented a higher percentage of Tc cells expressing TNF-α and IFN-γ (HG: 44.50±16.62 versus R: 61.47±20.54, P=0.014; and HG: 40.62±15.36 versus R: 52.39±18.66, P=0.049, respectively). Conclusion: The dynamic of different functional T cell subpopulations is significantly altered in CHF, which results in an exacerbated pro-inflammatory response, which could be due, at least in part, to the inability of CRT to restore Treg cells levels or inhibit Tc1 cell-mediated pro-inflammatory pathway.Trial registration: Retrospectively registered.
No takes yet. Share an insight, caveat, or question.
António et al. (2022) conducted a cohort in Chronic heart failure (n=50). Cardiac resynchronization therapy (CRT) vs. Healthy controls and baseline (pre-CRT) was evaluated on T regulatory (Treg) cells frequency (p=0.003). Cardiac resynchronization therapy failed to restore the significantly decreased levels of regulatory T cells in patients with chronic heart failure at 6 months follow-up.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: